Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...